Related Experiment Videos
A possible role for transforming growth factor-beta in systemic sclerosis
1Department of Medicine, Medical University of South Carolina, Charleston 29425.
Abstract:
The cause of systemic sclerosis remains unknown, but cellular and molecular mechanisms possibly responsible for the characteristic clinical manifestations of fibrosis and vascular damage (Raynaud's phenomenon, telangiectasis, digital infection, and renal arteriopathy) are becoming understood in greater detail. One possibly important cytokine is transforming growth factor-beta (TGF-beta); its involvement is reviewed here. With regard to vascular lesions, TGF-beta has variably been shown to inhibit endothelial cell growth in vitro but to promote angiogenesis in vivo, a paradox that remains unresolved. Nonetheless, an injurious activity of TGF-beta on microvascular endothelial cells could help to explain the intimal proliferation and microvascular obliteration seen. Whether as a result of or as a cause of endothelial cell damage, platelet activation has been well documented in systemic sclerosis and the platelet alpha granule pool contains a large quantity of TGF-beta. TGF-beta is also produced by activated macrophages and T cells, both of which are known to occur within systemic sclerosis lesions. An important effect of TGF-beta is its stimulation of fibroblast collagen and fibronectin synthesis and their deposition into the extracellular matrix. Stimulation by TGF-beta may therefore account for the fibrosis seen in the dermis and in the internal organs. Direct evidence of TGF-beta involvement in systemic sclerosis is scanty, and awaits discovery of either an abnormal expression of or response to TGF-beta. The biologic effects of TGF-beta appear to be regulated at the level of activation from a latent polypeptide precursor form. Descriptions of the importance of this cytokine in pathologic conditions will need to account for this activation and its regulation. Nonetheless, the physiologic effects so far attributed to TGF-beta make its involvement in systemic sclerosis an attractive possibility to explain some of the manifestations of this enigmatic disease.
Insights
Transforming growth factor-beta (TGF-beta) may play a role in systemic sclerosis, potentially explaining fibrosis and vascular damage. Further research is needed to confirm TGF-beta
Area of Science:
- Immunology
- Cell Biology
- Rheumatology
Background:
- Systemic sclerosis is characterized by fibrosis and vascular damage.
- The exact cause of systemic sclerosis remains unknown.
- Transforming growth factor-beta (TGF-beta) is a key cytokine implicated in fibrotic and vascular processes.
Purpose of the Study:
- To review the potential role of TGF-beta in the pathogenesis of systemic sclerosis.
- To explore the mechanisms by which TGF-beta may contribute to fibrosis and vascular lesions.
- To highlight the need for direct evidence of TGF-beta involvement in systemic sclerosis.
Main Methods:
- Literature review of studies on TGF-beta and systemic sclerosis.
- Analysis of TGF-beta's known effects on endothelial cells, platelets, macrophages, T cells, and fibroblasts.
- Discussion of the paradoxical effects of TGF-beta on angiogenesis.
Main Results:
- TGF-beta may contribute to vascular lesions through effects on endothelial cells and platelet activation.
- TGF-beta stimulates fibroblast collagen and fibronectin synthesis, potentially causing fibrosis.
- TGF-beta is found in platelets, macrophages, and T cells within systemic sclerosis lesions.
Conclusions:
- TGF-beta is an attractive candidate cytokine to explain key manifestations of systemic sclerosis.
- Further research is required to establish direct evidence of abnormal TGF-beta expression or response in systemic sclerosis.
- Understanding TGF-beta activation and regulation is crucial for elucidating its role in the disease.